Medical Management of Opioid-Induced Constipation

Publication Date: January 1, 2019

Treatment

Summary of Recommendations of AGA Clinical Guidelines for the Medical Management of OIC

Traditional laxatives

In patients with OIC, AGA recommends use of laxatives as first-line agents. ( Moderate , Strong )
612

Peripherally-acting µ-opioid receptor antagonists

In patients with laxative refractory OIC, AGA recommends naldemedine over no treatment. ( High , Strong )
612
In patients with laxative refractory OIC, AGA recommends naloxegol over no treatment. ( Moderate , Strong )
612
In patients with laxative refractory OIC, AGA suggests methylnaltrexone over no treatment. ( Low , Conditional (weak) )
612

Intestinal secretagogues

In patients with OIC, AGA makes no recommendation for the use of lubiprostone. ( Evidence Gap , No recommendation )
612

Selective 5-HT agonists

In patients with OIC, AGA makes no recommendation for the use of prucalopride. ( Evidence Gap , No recommendation )
612

Recommendation Grading

Disclaimer

Overview

Title

Medical Management of Opioid-Induced Constipation

Authoring Organization

Publication Month/Year

January 1, 2019

Document Type

Guideline

External Publication Status

Published

Country of Publication

US

Target Patient Population

Adults with opioid-induced constipation

Inclusion Criteria

Male, Female, Adult, Older adult

Health Care Settings

Ambulatory, Hospital, Outpatient

Intended Users

Nurse, nurse practitioner, physician, physician assistant

Scope

Treatment, Management

Diseases/Conditions (MeSH)

D000079689 - Opioid-Induced Constipation

Keywords

opioids, constipation, OIC, Opioid Induced Constipation

Supplemental Methodology Resources

Technical Review